Envista Holdings (NVST) Other Non-Current Liabilities (2018 - 2026)
Envista Holdings (NVST) recorded quarterly Other Non-Current Liabilities of $161.4 million in Q2 2026, little changed quarter-over-quarter from $161.4 million in Q4 2025, and up 9.42% on a YoY basis from $147.5 million in Q2 2025.
Envista Holdings (NVST) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Envista Holdings' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $161.4 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities rose 9.42% year-over-year to $161.4 million; the TTM figure through Apr 2026 stood at $161.4 million (up 9.42% YoY), while the FY2025 annual figure was $161.4 million, up 15.45% from the prior year.
- Other Non-Current Liabilities was $161.4 million for Q2 2026 at Envista Holdings, roughly flat from $161.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $288.2 million in Q2 2022 to a low of $136.7 million in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $167.3 million across 5 years, with a median of $151.3 million in 2022.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities tumbled 51.53% in 2022, then climbed 16.2% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $151.3 million in 2022, then dropped by 5.88% to $142.4 million in 2023, then dropped by 1.83% to $139.8 million in 2024, then gained by 15.45% to $161.4 million in 2025, then changed by 0.0% to $161.4 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $161.4 million (Q2 2026), $161.4 million (Q4 2025), and $169.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn |
| 10 | Envista Holdings | 4.06 Bn | 2.98 Bn | 390.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 161.40 Mn |
| Dec 31, 2025 | 161.40 Mn |
| Sep 26, 2025 | 169.70 Mn |
| Jun 27, 2025 | 171.40 Mn |
| Mar 28, 2025 | 147.50 Mn |
| Dec 31, 2024 | 139.80 Mn |
| Sep 27, 2024 | 149.70 Mn |
| Jun 28, 2024 | 147.50 Mn |
| Mar 29, 2024 | 136.70 Mn |
| Dec 31, 2023 | 142.40 Mn |
| Sep 29, 2023 | 150.50 Mn |
| Jun 30, 2023 | 153.00 Mn |
| Mar 31, 2023 | 151.30 Mn |
| Dec 31, 2022 | 151.30 Mn |
| Sep 30, 2022 | 220.70 Mn |
| Jul 1, 2022 | 201.30 Mn |
| Apr 1, 2022 | 288.20 Mn |
| Dec 31, 2021 | 304.20 Mn |
| Oct 1, 2021 | 318.20 Mn |
| Jul 2, 2021 | 415.30 Mn |